
Dr. Akhila Kosaraju is the CEO and President of Phare Bio, a biotech social venture pioneering the use of generative AI to discover novel antibiotics in partnership with the Collins Lab at MIT. Phare launched with support from TED’s Audacious Project, has been awarded $27M from ARPA-H, and recently received support from Google.org’s Generative AI Accelerator. The company has also been recognized by Fast Company, Newsweek, and WIRED Health for its groundbreaking work at the intersection of AI and antibiotic discovery. A physician and biotech executive, Dr. Kosaraju has led efforts across startups, government, and global health. She previously served as founding CEO of Variant Bio, an executive at SIGA Technologies, and a White House appointee in the Pentagon helping to oversee the Military Health System. She is a Member of the Council on Foreign Relations, co-founder of the Alliance to End Biological Threats, and a Lecturer at Stanford. She earned her M.D. from Columbia and her B.A. from Stanford.